Cholinergic interneurons in the Q140 knockin mouse model of Huntington’s disease: Reductions in dendritic branching and thalamostriatal input

Journal of Comparative Neurology

Volumn 524, Issue 17, 2016, Pages 3518-3529

  Deng, Yun Ping ^a   Reiner, Anton ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

AB_2301731; AB_90650; cholinergic interneurons; corticostriatal; Huntington's disease; pathology; premanifest; striatum; thalamostriatal

Indexed keywords

CHOLINE ACETYLTRANSFERASE; GLUTAMATE RECEPTOR 2; SLC17A6 PROTEIN, MOUSE; VESICULAR GLUTAMATE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL DENSITY; CELL LOSS; CELL SIZE; CHOLINERGIC NERVE CELL; CORPUS STRIATUM; DENDRITIC CELL; GENOTYPE; HUNTINGTON CHOREA; LIFESPAN; MALE; NERVE ENDING; NERVE GROWTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SYNAPTIC TRANSMISSION; THALAMUS; ANIMAL; AXON; DENDRITE; DISEASE MODEL; ELECTRON MICROSCOPY; GENE TARGETING; IMMUNOHISTOCHEMISTRY; INTERNEURON; METABOLISM; NERVE TRACT; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; AXONS; CELL COUNT; CELL SIZE; CHOLINE O-ACETYLTRANSFERASE; CHOLINERGIC NEURONS; CORPUS STRIATUM; DENDRITES; DISEASE MODELS, ANIMAL; GENE KNOCK-IN TECHNIQUES; HUNTINGTON DISEASE; IMMUNOHISTOCHEMISTRY; INTERNEURONS; MALE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON; NEURAL PATHWAYS; THALAMUS; VESICULAR GLUTAMATE TRANSPORT PROTEIN 2;

EID: 84973483653     PISSN: 00219967     EISSN: 10969861     Source Type: Journal    
DOI: 10.1002/cne.24013     Document Type: Article

References (81)

1. Albin RL, Young AB, Penney JB. 1989. The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366–375.
2. Albin RL, Qin Y, Young AB, Penney JB, Chesselet MF. 1991. Preproenkephalin messenger RNA-containing neurons in striatum of patients with symptomatic and presymptomatic Huntington's disease: an in situ hybridization study. Ann Neurol 30:542–549.
3. Augood SJ, Faull RL, Emson PC. 1997. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol 42:215–221.
4. Aylward EH. 2007. Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res Bull 72:152–158.
5. Aylward EH, Nopoulos PC, Ross CA, Langbehn DR, Pierson RK, Mills JA, Johnson HJ, Magnotta VA, Juhl AR, Paulsen JS. 2011. PREDICT-HD Investigators and Coordinators of Huntington Study Group (HSG). Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 82:405–410.
6. Aylward EH, Liu D, Nopoulos PC, Ross CA, Pierson RK, Mills JA, Long JD, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group. 2012. Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol Psychiat 71:822–828.
7. Aylward EH, Harrington DL, Mills JA, Nopoulos PC, Ross CA, Long JD, Liu D, Westervelt HK, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group. 2013. Regional atrophy associated with cognitive and motor function in prodromal Huntington disease. J Huntington Dis Res 2:477–489.
8. Bechtel N, Scahill RI, Rosas HD, Acharya T, van den Bogaard SJ, Jauffret C, Say MJ, Sturrock A, Johnson H, Onorato CE, Salat DH, Durr A, Leavitt BR, Roos RA, Landwehrmeyer GB, Langbehn DR, Stout JC, Tabrizi SJ, Reilmann R. 2010. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology 75:2150–2160.
9. Berendse HW, Groenewegen HJ. 1990. Organization of the thalamostriatal projections in the rat, with special emphasis on the ventral striatum. J Comp Neurol 299:187–228.
10. Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, Carlozzi NE, Duff K, Beglinger LJ, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group (HSG). 2009. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord 24:1763–1772.
11. Blekher TM, Yee RD, Kirkwood SC, Hake AM, Stout JC, Weaver MR, Foroud TM. 2004. Oculomotor control in asymptomatic and recently diagnosed individuals with the genetic marker for Huntington's disease. Vision Res 44:2729–2736.
12. Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, Penney JB, Bates GP, Young AB. 1998. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci USA 95:6480–6485.
13. Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, Squitieri F. 2006. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med 47:215–222.
14. Coulon P, Bras H, Vinay L. 2011. Characterization of last-order premotor interneurons by transneuronal tracing with rabies virus in the neonatal mouse spinal cord. J Comp Neurol 519:3470–3487.
15. de Boo GM, Tibben A, Lanser JB, Jennekens-Schinkel A, Hermans J, Maat-Kievit A, Roos RA. 1997. Early cognitive and motor symptoms in identified carriers of the gene for Huntington disease. Arch Neurol 54:1353–1357.
16. Delval A, Bleuse S, Simonin C, Delliaux M, Rolland B, Destee A, Defebvre L, Krystkowiak P, Dujardin K. 2011. Are gait initiation parameters early markers of Huntington's disease in pre-manifest mutation carriers? Gait Posture 34:202–207.
17. Deng YP, Albin RL, Penney JB, Young AB, Anderson KD, Reiner A. 2004. Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J Chem Neuroanat 27:143–164.
18. Deng YP, Wong T, Bricker-Anthony C, Deng B, Reiner A. 2013. Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice. Neurobiol Dis 60:89–107.
19. Deng YP, Wong T, Wan JY, Reiner A. 2014. Differential loss of thalamostriatal and corticostriatal input to striatal projection neuron types prior to overt motor symptoms in the Q140 knock-in mouse model of Huntington's disease. Front Syst Neurosci 8:198.
20. Desban M, Kemel ML, Glowinski J, Gauchy C. 1993. Spatial organization of patch and matrix compartments in the rat striatum. Neuroscience 57:661–667.
21. Ding JB, Guzman JN, Peterson JD, Goldberg JA, Surmeier DJ. 2010. Thalamic gating of corticostriatal signaling by cholinergic interneurons. Neuron 67:294–307.
22. DiProspero NA, Chen EY, Charles V, Plomann M, Kordower JH, Tagle DA. 2004. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol 33:517–533.
23. Dumas EM, van den Bogaard SJ, Ruber ME, Reilman RR, Stout JC, Craufurd D, Hicks SL, Kennard C, Tabrizi SJ, van Buchem MA, van der Grond J, Roos RA. 2012. Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease. Human Brain Mapp 33:203–212.
24. Farrar A, Callahan JW, Abercrombie ED. 2011. Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: an examination of the role of altered inhibitory and excitatory mechanisms. Exp Neurol 232:119–125.
25. Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, Paulsen JS, Dhawan V, Eidelberg D. 2007. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 130:2858–2867.
26. Ferrante RJ, Beal MF, Kowall NW, Richardson EP Jr, Martin JB. 1987. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res 411:162–166.
27. Ferreira T, Blackman A, Oyrer J, Jayabal A, Chung A, Watt A, Sjöström J, van Meyel D. 2014, Neuronal morphometry directly from bitmap images. Nature Methods 11:982–984.
28. Fowler SC, Muma NA. 2015. Use of a force-sensing automated open field apparatus in a longitudinal study of multiple behavioral deficits in CAG140 Huntington's disease model mice. Behav Brain Res 294:7–16.
29. Fusco FR, Chen Q, Lamoreaux WJ, Figueredo-Cardenas G, Jiao Y, Coffman JA, Surmeier DJ, Honig MG, Carlock LR, Reiner A. 1999. Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. J Neurosci 19:1189–1202.
30. Gerfen CR. 1992. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci 15:285–320.
31. Glass M, Dragunow M, Faull RLM. 2000. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAa receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97:505–519.
32. Grafton ST, Mazziotta JC, Pahl JJ, St George-Hyslop P, Haines JL, Gusella J, Hoffman JM, Baxter LR, Phelps ME. 1992. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch Neurol 49:1161–1167.
33. Guillery RW, Herrup K. 1997. Quantification without pontification: choosing a method for counting objects in sectioned tissues. J Comp Neurol 386:2–7.
34. Hedreen JC, Folstein SE. 1995. Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol Exp Neurol 54:105–120.
35. Heinsen H, Rüb U, Bauer M, Ulmar G, Bethke B, Schüler M, Böcker F, Eisenmenger W, Götz M, Korr H, Schmitz C. 1999. Nerve cell loss in the thalamic mediodorsal nucleus in Huntington's disease. Acta Neuropathol 97:613–622.
36. Hickey MA, Kosmalska A, Enayati J, Cohen R, Zeitlin S, Levine MS, Chesselet MF. 2008. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience 157:280–295.
37. Hickey MA, Zhu C, Medvedeva V, Lerner RP, Patassini S, Franich NR, Maiti P, Frautschy SA, Zeitlin S, Levine MS, Chesselet MF. 2012. Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease. Mol Neurodegen 7:12.
38. Hobbs NZ, Barnes J, Frost C, Henley SM, Wild EJ, Macdonald K, Barker RA, Scahill RI, Fox NC, Tabrizi SJ. 2010. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. Am J Neuroradiol 31:1036–1041.
39. Holley SM, Joshi PR, Parievsky A, Galvan L, Chen JY, Fisher YE, Huynh MN, Cepeda C, Levine MS. 2015. Enhanced GABAergic inputs contribute to functional alterations of cholinergic interneurons in the R6/2 mouse model of Huntington's disease. eNeuro 2, pii:e0008.
40. Kipps CM, Duggins AJ, Mahant N, Gomes L, Ashburner J, McCusker EA. 2005. Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry 76:650–655.
41. Kirkwood SC, Siemers E, Stout JC, Hodes ME, Conneally PM, Christian JC, Foroud T. 1999. Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch Neurol 56:563–568.
42. Kirkwood SC, Siemers E, Bond C, Conneally PM, Christian JC, Foroud T. 2000. Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene. Arch Neurol 57:1040–1044.
43. Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, Albin R, Shelbourne P, Delorenzi M, Augood SJ, Faull RL, Olson JM, Bates GP, Jones L, Luthi-Carter R. 2007. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 16:1845–1861.
44. Lapper SR, Bolam JP. 1992. Input from the frontal cortex and the parafascicular nucleus to cholinergic interneurons in the dorsal striatum of the rat. Neuroscience 51:533–545.
45. Lei W, Deng YP, Liu BB, Mu SH, Guley NM, Wong T, Reiner A. 2013. A confocal laser scanning microscopy and ultrastructural study of VGLUT2 thalamic input to striatal projection neurons in rats. J Comp Neurol 521:1354–1377.
46. Lerner RP, Trejo Martinez Ldel C, Zhu C, Chesselet MF, Hickey MA. 2012. Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease. Brain Res Bull 87:571–578.
47. Lim SA, Kang UJ, McGehee DS. 2014. Striatal cholinergic interneuron regulation and circuit effects. Front Synaptic Neurosci 6:22.
48. Menalled LB, Sison JD, Wu Y, Olivieri M, Li XJ, Li H, Zeitlin S, Chesselet MF. 2002. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J Neurosci 22:8266–8276.
49. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF. 2003. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 465:11–26.
50. Molero AE, Gokhan S, Gonzalez S, Feig JL, Alexandre LC, Mehler MF. 2009. Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease. Proc Natl Acad Sci U S A 106:21900–21905.
51. Nopoulos PC, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, Juhl AR, Pierson RK, Mills J, Langbehn DR, Paulsen JS; PREDICT-HD Investigators Coordinators of Huntington Study Group (HSG). 2010. Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis 40:544–554.
52. Paulsen JS, Zimbelman JL, Hinton SC, Langbehn DR, Leveroni CL, Benjamin ML, Reynolds NC, Rao SM. 2004. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's disease. Am J Neuroradiol 25:1715–1721.
53. Paulsen JS, Magnotta VA, Mikos AE, Paulson HL, Penziner E, Andreasen NC, Nopoulos PC. 2006. Brain structure in preclinical Huntington's disease. Biol Psychiatry 59:57–63.
54. 18F-fluoroethoxybenzovesamicol: biodistribution, dosimetry, and tracer kinetic analyses. J Nucl Med 55:396–404.
55. Phelps PE, Houser CR, Vaughn JE. 1985. Immunocytochemical localization of choline acetyltransferase within the rat neostriatum: a correlated light and electron microscopic study of cholinergic neurons and synapses. J Comp Neurol 238:286–307.
56. Pisani A, Bernardi G, Ding J, Surmeier DJ. 2007. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci 30:545–553.
57. Rao AK, Muratori L, Louis ED, Moskowitz CB, Marder KS. 2008. Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease. Mov Disord 23:1100–1107.
58. Rao AK, Gordon AM, Marder KS. 2011. Coordination of fingertip forces during precision grip in premanifest Huntington's disease. Mov Disord 26:862–869.
59. Reading SA, Yassa MA, Bakker A, Dziorny AC, Gourley LM, Yallapragada V, Rosenblatt A, Margolis RL, Aylward EH, Brandt J, Mori S, van Zijl P, Bassett SS, Ross CA. 2005. Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res 140:55–62.
60. Rising AC, Xu J, Carlson A, Napoli VV, Denovan-Wright EM, Mandel RJ. 2011. Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats. Exp Neurol 228:173–182.
61. Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME, Caplan K, Marek K, Seidman LJ, Makris N, Jenkins BG, Goldstein JM. 2003. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 60:1615–1620.
62. Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B. 2005. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 65:745–747.
63. Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM, Salat DH. 2006. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov Disord 21:1317–1325.
64. Shiromani PJ, Armstrong DM, Bruce G, Hersh LB, Groves PM, Gillin JC. 1987. Relation of pontine choline acetyltransferase immunoreactive neurons with cells which increase discharge during REM sleep. Brain Res Bull 18:447–455.
65. Sholl DA. 1953. Dendritic organization in the neurons of the visual and motor cortices of the cat. J Anat 87:387–406.
66. Siemers E, Foroud T, Bill DJ, Sorbel J, Norton JA Jr, Hodes ME, Niebler G, Conneally PM, Christian JC. 1996. Motor changes in presymptomatic Huntington disease gene carriers. Arch Neurol 53:487–492.
67. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR. 2003. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12:1555–1567.
68. Smith R, Chung H, Rundquist S, Maat-Schieman ML, Colgan L, Englund E, Liu YJ, Roos RA, Faull RL, Brundin P, Li JY. 2006. Cholinergic neuronal defect without cell loss in Huntington's disease. Hum Mol Genet 15:3119–3131.
69. Smith Y, Surmeier DJ, Redgrave P, Kimura M. 2011. Thalamic contributions to basal ganglia-related behavioral switching and reinforcement. J Neurosci 31:16102–16106.
70. Spokes EG. 1980 Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. Brain 103:179–210.
71. Strand AD, Baquet ZC, Aragaki AK, Holmans P, Yang L, Cleren C, Beal MF, Jones L, Kooperberg C, Olson JM, Jones KR. 2007. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci 27:11758–11768.
72. Suzuki M, Desmond TJ, Albin RL, Frey KA. 2001 Vesicular neurotransmitter transporter in Huntington's disease: initial observations and comparison with traditional synaptic markers. Synapse 41:329–336.
73. Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC, TRACK-HD Investigators. 2011. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 10:31–42.
74. Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR; TRACK-HD Investigators. 2013. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12:637–647.
75. Turner TH, Goldstein J, Hamilton JM, Jacobson M, Pirogovsky E, Peavy G, Corey-Bloom J. 2011. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. J Mot Behav 43:295–302.
76. Vetter JM, Jehle T, Heinemeyer J, Franz P, Behrens PF, Jackisch R, Landwehrmeyer GB, Feuerstein TJ. 2003 Mice transgenic for exon 1 of Huntington's disease: properties of cholinergic and dopaminergic presynaptic function in the striatum. J Neurochem 85:1054–1063.
77. Vonsattel JP, DiFiglia M. 1998. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 57:369–384.
78. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. 1985. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44:559–577.
79. Wang HB, Deng YP, Reiner A. 2007. In situ hybridization histochemical and immunohistochemical evidence that striatal projection neurons cocontaining substance P and enkephalin are overrepresented in the striosomal compartment of striatum in rats. Neurosci Lett 425:195–199.
80. Wilson CJ, Groves PM, Kitai ST, Linder JC. 1983. Three-dimensional structure of dendritic spines in the rat neostriatum. J Neurosci 3:383–388.
81. Wolf RC, Grön G, Sambataro F, Vasic N, Wolf ND, Thomann PA, Saft C, Landwehrmeyer GB, Orth M. 2012. Brain activation and functional connectivity in premanifest Huntington's disease during states of intrinsic and phasic alertness. Hum Brain Mapp 33:2161–2173.